• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便微生物群移植产品的监管考虑因素。

Regulatory Considerations for Fecal Microbiota Transplantation Products.

机构信息

Laboratory of Mucosal Pathogens and Cellular Immunology, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

出版信息

Cell Host Microbe. 2020 Feb 12;27(2):173-175. doi: 10.1016/j.chom.2020.01.018.

DOI:10.1016/j.chom.2020.01.018
PMID:32053787
Abstract

Fecal microbiota for transplantation (FMT) is being studied as a potential intervention for numerous conditions. The regulation of FMT by the FDA is discussed along with FMT donor screening and manufacturing considerations. The FDA is committed to ensuring that FMT products can be safely tested in clinical trials.

摘要

粪便微生物群移植(FMT)正在被研究作为许多疾病的一种潜在干预手段。本文讨论了 FDA 对 FMT 的监管,以及 FMT 供体筛选和生产方面的考虑。FDA 致力于确保 FMT 产品能够在临床试验中安全地进行测试。

相似文献

1
Regulatory Considerations for Fecal Microbiota Transplantation Products.粪便微生物群移植产品的监管考虑因素。
Cell Host Microbe. 2020 Feb 12;27(2):173-175. doi: 10.1016/j.chom.2020.01.018.
2
Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes.衰老对粪菌移植供体粪便微生物群组成的影响及其对临床结局的影响。
Dig Dis Sci. 2017 Apr;62(4):1002-1008. doi: 10.1007/s10620-017-4449-6. Epub 2017 Feb 8.
3
Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.用于复发性艰难梭菌感染的粪便微生物群移植供体及粪便样本的实验室检测
J Clin Microbiol. 2017 Apr;55(4):1002-1010. doi: 10.1128/JCM.02327-16. Epub 2017 Jan 11.
4
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.造血干细胞移植受者复发性艰难梭菌感染的粪便微生物群移植
Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.
5
Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.完全微生物群植入对于粪便微生物群移植后复发性艰难梭菌感染的恢复并非必不可少。
mBio. 2016 Dec 20;7(6):e01965-16. doi: 10.1128/mBio.01965-16.
6
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.粪便微生物群移植治疗艰难梭菌感染
J Hosp Med. 2016 Jan;11(1):56-61. doi: 10.1002/jhm.2449. Epub 2015 Sep 7.
7
Fecal microbiota transplantation: History, procedure and regulatory considerations.粪便微生物群移植:历史、程序和监管考虑因素。
Presse Med. 2023 Dec;52(4):104204. doi: 10.1016/j.lpm.2023.104204. Epub 2023 Nov 7.
8
[Fecal microbiota transplantation, a novel therapy for recurrent Clostridium difficile infection].[粪便微生物群移植,一种治疗复发性艰难梭菌感染的新疗法]
Ned Tijdschr Tandheelkd. 2016 Sep;123(9):406-9. doi: 10.5177/ntvt.2016.09.16146.
9
Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation.预测包裹粪菌移植后艰难梭菌感染的复发。
Microbiome. 2018 Sep 18;6(1):166. doi: 10.1186/s40168-018-0549-6.
10
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.

引用本文的文献

1
Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.神经退行性疾病中的微生物群-肠道-脑轴:分子机制与治疗靶点
Mol Biomed. 2025 Sep 15;6(1):64. doi: 10.1186/s43556-025-00307-1.
2
Fundamentals of microbiome-based therapies for reproductive tract inflammatory diseases in domestic animals.家畜生殖道炎症性疾病的基于微生物组疗法的基础
Anim Reprod. 2025 Sep 1;22(3):e20250030. doi: 10.1590/1984-3143-AR2025-0030. eCollection 2025.
3
Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension.
微生物群移植疗法在肺动脉高压中是安全可行的。
JACC Basic Transl Sci. 2025 Aug 12;10(9):101347. doi: 10.1016/j.jacbts.2025.101347.
4
Microbiota and kidney disease: the road ahead.微生物群与肾脏疾病:未来之路
Nat Rev Nephrol. 2025 Oct;21(10):702-716. doi: 10.1038/s41581-025-00988-5. Epub 2025 Jul 28.
5
Gut microbiota and sepsis-associated encephalopathy: pathogenesis and precision therapies.肠道微生物群与脓毒症相关性脑病:发病机制与精准治疗
Front Neurosci. 2025 Jul 8;19:1596467. doi: 10.3389/fnins.2025.1596467. eCollection 2025.
6
Regulatory framework and challenges for live biotherapeutic products in Taiwan.台湾地区活生物治疗产品的监管框架与挑战
J Food Drug Anal. 2025 Jun 13;33(2):97-105. doi: 10.38212/2224-6614.3540.
7
Gut-derived from exceptional responders mitigates chemoradiotherapy-induced intestinal injury through methionine-driven epigenetic modulation.来自超反应者的肠道源物质通过蛋氨酸驱动的表观遗传调控减轻放化疗引起的肠道损伤。
Imeta. 2025 May 14;4(3):e70043. doi: 10.1002/imt2.70043. eCollection 2025 Jun.
8
Oncobiomics: Leveraging Microbiome Translational Research in Immuno-Oncology for Clinical-Practice Changes.肿瘤生物组学:利用免疫肿瘤学中的微生物组转化研究推动临床实践变革。
Biomolecules. 2025 Mar 31;15(4):504. doi: 10.3390/biom15040504.
9
Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape.粪菌移植治疗复发性艰难梭菌感染及其全球监管格局。
Indian J Med Res. 2025 Feb;161(2):113-119. doi: 10.25259/IJMR_818_2024.
10
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.肠道菌群失调相关疾病的粪便微生物群移植研究进展
Adv Sci (Weinh). 2025 Apr;12(13):e2413197. doi: 10.1002/advs.202413197. Epub 2025 Feb 27.